CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Company previously received approval from swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland for the study Execution of global patient enrollment continues to progress in pivotal study of Berubicin for the treatment of GBM, one of the most aggressive forms of brain cancer HOUSTON, April 5, 2022 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has received approval from Swissmedic, the Swiss Agency for Therapeutic Products, for the Company’s potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM). With approvals now received from both swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland, and Swissmedic, the Company can proceed with site initiation and patient enrollment in Switzerland.

The release as fetched from its publisher. cnspharma.com ↗